Early-onset AD – a call for clinical trial inclusion
Alzheimer’s disease (AD) is a significant public health burden and has huge devastating effects at an individual level. For over two decades, an arbitrary… Read more »
Latest posts by Alexander Kroll (see all)
- Early-onset AD – a call for clinical trial inclusion - 9th February 2011
- New series in Alzheimer’s Research & Therapy explores prevention trials - 29th October 2010
- sMRI – the most powerful Alzheimer’s disease biomarker? - 2nd September 2010
New series in Alzheimer’s Research & Therapy explores prevention trials
Alzheimer’s disease (AD) almost certainly begins to develop before cognitive decline in an individual becomes apparent, which is why an increasing amount of… Read more »
sMRI – the most powerful Alzheimer’s disease biomarker?
Apart from the formation of neurofibrillary tangles and deposition of amyloid plaques, other hallmarks of Alzheimer’s disease (AD) include the loss of both… Read more »
Uncovering the role of proteases in neurodegeneration
Alzheimer’s disease (AD) is associated with a progressive accumulation of senile plaques (containing β-amyloid (Aβ)) and neurofibrillary tangles, but the… Read more »